MK-8666

MK-8666 is a potent and selective partial GPR40 agonist (EC50 = 0.54 nM for human GPR40) . MK-8666 shows selectivity over GPR119, GPR43, GPR41, GPR120, and other G-protein-coupled receptors (GPCRs) . MK-8666 reduces glucose in the rodent. MK-8666 can be used for type 2 diabetes research[1][2].

1544739-75-4

12352005

Free Fatty Acid Receptor

GPCR/G Protein

Metabolism-sugar/lipid metabolism

Metabolic Disease

O=C(O)[C@H]1[C@]([H])(CC2=C3C=NC(OCC4=CC(C5=C(C=C(C=C5C)OCCCS(=O)(C)=O)C)=CC=C4)=C2)[C@@]13[H]

C29H31NO6S

521.62

[1]Krug AW, et al. Leveraging a Clinical Phase Ib Proof-of-Concept Study for the GPR40 Agonist MK-8666 in Patients With Type 2 Diabetes for Model-Informed Phase II Dose Selection. Clin Transl Sci. 2017 Sep;10 (5) :404-411.|[2]Pachanski MJ, et al. GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent. PLoS One. 2017 Oct 20;12 (10) :e0186033.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-W727728/

Reference compound1

No Development Reported